- Home
- EWCZ vs PLYX Comparison
EWCZ vs PLYX Comparison
Compare EWCZ & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EWCZ | PLYX |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.7M | 271.8M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | EWCZ | PLYX |
|---|---|---|
| Price | $5.82 | $5.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $5.87 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 390.6K | 173.8K |
| Earning Date | 05-13-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.76 | N/A |
| Revenue Next Year | $2.29 | N/A |
| P/E Ratio | $21.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.95 | $2.20 |
| 52 Week High | $6.52 | $9.18 |
Technical Indicators
Market Signals| Indicator | EWCZ | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 48.81 |
| Support Level | $3.53 | $4.95 |
| Resistance Level | $5.90 | $7.32 |
| Average True Range (ATR) | 0.02 | 0.61 |
| MACD | -0.02 | -0.15 |
| Stochastic Oscillator | 30.00 | 36.54 |
Price Performance
Historical ComparisonAbout EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services, and others.
About PLYX Polaryx Therapeutics Inc. Common Stock
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.